<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7509820\results\search\drug\results.xml">
  <result pre="with high risk factors for severe illness patients. Lopinavir/ritonavir and" exact="ribavirin" post="alone are not recommended for COVID-19 patients. Lopinavir and"/>
  <result pre="ribavirin alone are not recommended for COVID-19 patients. Lopinavir and" exact="ritonavir" post="Lopinavir and ritonavir is widely used as a boosted"/>
  <result pre="not recommended for COVID-19 patients. Lopinavir and ritonavir Lopinavir and" exact="ritonavir" post="is widely used as a boosted protease inhibitor in"/>
  <result pre="inhibitor in the treatment of HIV infection [50]. Lopinavir and" exact="ritonavir" post="can block the enzymes that required for virus replication."/>
  <result pre="that required for virus replication. Lopinavir is often combined with" exact="ritonavir" post="to extend the half-life of lopinavir by the inhibition"/>
  <result pre="is often combined with ritonavir to extend the half-life of" exact="lopinavir" post="by the inhibition of cytochrome P450 [51]. A study"/>
  <result pre="P450 [51]. A study had found that the Lopinavir and" exact="ritonavir" post="combined with ribavirin in the treatment of SARS was"/>
  <result pre="study had found that the Lopinavir and ritonavir combined with" exact="ribavirin" post="in the treatment of SARS was associated with better"/>
  <result pre="better effect [52]. And animal studies show that Lopinavir and" exact="Ritonavir" post="can reduce levels of coronavirus that cause SARS and"/>
  <result pre="signal, the test has limitations and still needs follow-up discussion." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine, a widely used antimalarial and autoimmune"/>
  <result pre="test has limitations and still needs follow-up discussion. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine, a widely used antimalarial and autoimmune disease drug,"/>
  <result pre="reported may be a potential broad-spectrum antiviral drug [57, 58]." exact="Chloroquine" post="blocks viral infection by increasing endosomal pH required for"/>
  <result pre="SARS-CoV cellular receptor [59]. A study showed that remdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19 infection"/>
  <result pre="of COVID-19 infection in vitro [60]. Therefore, the efficacy of" exact="Chloroquine" post="needs to be clarified and applied to patients as"/>
  <result pre="be clarified and applied to patients as soon as possible." exact="Hydroxychloroquine" post="is a derivative of chloroquine. The two structures are"/>
  <result pre="and cough remission time of patients were significantly shortened in" exact="hydroxychloroquine" post="group. The proportion of patients with improved pneumonia was"/>
  <result pre="was higher than that of the control group (54.8%) [61]." exact="Hydroxychloroquine" post="can significantly shorten the clinical recovery time of patients"/>
  <result pre="with new coronavirus and promote the improvement of pneumonia. However," exact="hydroxychloroquine" post="or combined azithromycin is not recommended for COVID-19 patients"/>
  <result pre="and promote the improvement of pneumonia. However, hydroxychloroquine or combined" exact="azithromycin" post="is not recommended for COVID-19 patients base on Chinaâ€™s"/>
  <result pre="the antiviral effects of chloroquineLancet Infect Dis200662676910.1016/S1473-3099(06)70361-916439323 58.YanYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza a H5N1"/>
  <result pre="of SARS coronavirus infection and spreadVirol J200526910.1186/1743-422X-2-6916115318 60.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res202030326932020029 61.ChenZet al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  <result pre="after lung cancer surgeryJAMA Oncol20173561061910.1001/jamaoncol.2016.582928056112 80.ZhongW-Zet al.Gefitinib versus vinorelbine plus" exact="cisplatin" post="as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC"/>
 </snippets>
</snippetsTree>
